RAF1 and SOS1 Gene Mutation Detection for Noonan Syndrome Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Noonan Syndrome are challenging due to phenotypic variations and the limited ability to identify mutations beyond PTPN11 and KRAS, which account for only 50% of cases, making early and accurate diagnosis difficult.
Innovation Solution
The development of methods to detect mutations in the RAF1 and SOS1 genes, including specific nucleotide substitutions and amino acid changes, to diagnose Noonan Syndrome by assessing gene activity and expression levels, using oligonucleotide probes and antibodies to identify variant polypeptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If clinical diagnosis based on phenotypic recognition is used, then diagnosis can be performed without genetic testing, but diagnostic accuracy is reduced due to phenotypic variations and subtle cases
Solution Approach 1:
The patent introduces genetic markers (mutations in PTPN11, KRAS, RAF1, and SOS1 genes) as intermediary indicators to bridge clinical diagnosis and genetic testing. These markers serve as detectable proxies that enable accurate identification of Noonan syndrome cases while maintaining clinical workflow simplicity.
Solution Approach 2:
The patent replaces the subjective clinical assessment mechanism with an objective genetic detection mechanism. By substituting phenotypic observation with molecular genetic testing, the system achieves higher diagnostic accuracy while maintaining ease of use through standardized genetic assays.
2Measurement precision
If genetic testing for PTPN11 and KRAS mutations is performed, then diagnostic accuracy improves for those cases, but coverage is limited to only 50% of suspected patients
Solution Approach 1:
The patent creates a universal diagnostic approach that tests for multiple gene mutations (PTPN11, KRAS, RAF1, and SOS1) within a single diagnostic framework. This multi-gene panel approach enables the system to accommodate and accurately diagnose diverse genetic causes of Noonan syndrome, expanding coverage to approximately 75% of suspected cases while maintaining high diagnostic accuracy.
Solution Approach 2:
The patent segments the diagnostic process into targeted genetic testing for specific genes and mutations associated with Noonan syndrome. By dividing the broad diagnostic challenge into specific genetic markers across multiple genes, the system achieves comprehensive coverage while maintaining precision through focused mutation detection.
3Loss of time
If facial characteristics are used for diagnosis, then early diagnosis is possible, but diagnosis becomes less apparent with progressing age
Solution Approach 1:
The patent enables preliminary genetic testing that can be performed on newborns or infants before phenotypic features fully manifest or before they become less apparent with age. By conducting genetic detection early in life, the system captures diagnostic information at the optimal time while avoiding the limitation of age-related symptom attenuation.
Solution Approach 2:
The patent replaces the time-sensitive phenotypic observation mechanism with a time-independent genetic detection mechanism. Genetic markers remain stable throughout life, allowing accurate diagnosis regardless of the patient's age or the visibility of facial characteristics, thereby eliminating the temporal limitation inherent in clinical diagnosis.
Data Source
AI summary
Diagnostic and therapeutic applications for Noonan Syndrome are described. The diagnostic and therapeutic applications are based on certain mutations in a RAS-specific guanine nucleotide exchange factor gene SOS1 or its expression product. The diagnostic and therapeutic applications are also based on certain mutations in a serine/threonine protein kinase gene RAF1 or its expression product thereof. Also described are nucleotide sequences, amino acid sequences, probes, and primers related to RAF1 or SOS1, and variants thereof, as well as host cells expressing such variants.